DIO2 (deiodinase, iodothyronine, type II)

2010-06-01   Ana Luiza Maia , Simone Magagnin Wajner , Leonardo B Leiria 

Thyroid Section, Endocrine Division, Hospital de Clinicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Identity

HGNC
LOCATION
14q31.1
LOCUSID
ALIAS
5DII,D2,DIOII,SELENOY,SelY,TXDI2

DNA/RNA

Atlas Image
Organization of the Dio2 gene: Yellow bars represent the coding region (exon) and red bars, the untranslated region.

Description

The Dio2 gene is composed of 3 exons comprising 14656 bp of the genomic DNA.

Transcription

The length of transcribed mRNA is about 6,8 kb and generates three variants of mRNA. Transcript variant 1 represents the longest transcript and encodes isoform a. Transcript variant 2 differs in the 5UTR when compared to variant 1. Both variants 1 and 2 encode isoform a. Transcript variant 3 includes an alternate in-frame exon in the coding region, compared to variant 1. Variant 3 encodes isoform b, which is longer than isoform a.

Pseudogene

No pseudogene have been described.

Proteins

Atlas Image
Schematic representation of D2 peptide structure (not on scale). Isoform a (273 aa) and Isoform b (309 aa). In deep green transmembran domain (position 10-34). In yellow active site (position 133). In deep blue alternative sequence isoform b (position 74).

Description

The protein encoded by this gene belongs to the iodothyronine deiodinase family. This enzyme activates thyroid hormone by converting the prohormone thyroxine (T4) by outer ring deiodination to bioactive 3,3,5-triiodothyronine (T3). It is highly expressed in the thyroid, and may contribute significantly to the relative increase in thyroidal T3 production in patients with Graves disease and thyroid adenomas. This protein contains selenocysteine (Sec) residues encoded by the UGA codon, which often signals the end of process of translation. The 3UTR of Sec-containing genes have a common stem-loop structure, the sec insertion sequence (SECIS), which is necessary for the recognition of UGA as a Sec codon rather than a stop signal. Alternative splicing results in multiple transcript variants encoding different isoforms. Ubiquitination can also regulate proteins by transiently inactivating enzymatic function through conformational change in a dimeric enzyme, which can be reversed upon deubiquitination (post-translational).

Expression

Ohba et al. (2001) identified 2 alternatively spliced DIO2 transcripts that include intronic sequences between the 2 invariant DIO2 exons. These splice variants showed tissue-specific expression in brain, thyroid, liver, thymus, anterior pituitary gland and brown adipose tissue. In mesothelioma cell lysates, Curcio et al. (2001) determined that endogenous DIO2 gene had an apparent molecular mass of 31 kD. In normal tissues, D2 activity/mRNA ratio is variable, but the enzyme is expressed in rodents in the developing and adult testis, heart, muscle, thyroid, BAT, brain, pituitary, thymus, skin, spinal cord, placenta, liver and pancreas. In humans D2 is expressed in brain, BAT, heart, thyroid, muscle, placenta, skin and vascular smooth muscle cells.

Localisation

Immuno location of the protein in cells showed D2 as an endoplasmic reticulum resident protein.

Function

Type 2 deiodinase converts intracellular pro-hormone-3,3,5,5-tetraiodothyronine (T4) into the active thyroid hormone 3,3,5-triiodothyronine (T3) thereby regulating intracellular levels of active T3 in target tissues.
Thermogenesis
The expression of D2 is increased in response to cold stimulation in brown adipocytes isolated from mice. Dio2 activation in the brown adipose tissue (BAT) of human newborns and rodents is known to play a role in adaptive energy expenditure during cold exposure.
Development
D2 activity is present in human placenta through all pregnancy, and is highly expressed during the first trimester. The level of activity is low in the non-pregnant uterus, but in pregnancy the level rises progressively to a maximum at gestation day 17 when it is increased threefold.

Homology

Several homologues of Dio2 have been identified in Pan troglodytes and Macaca mulatta (100%). The chicken and mouse have similar domain structures with human Dio2 (97%). Human Dio2 homology with D3 is expressed in Sus scrofia, Equus caballus, Cricetus cricetus, Oryctolagus cuniculus, Pituophis deppei (92% similarity) and limited domains with human D3 and D1.

Mutations

Note

No germinal or somatic mutations has been described. However, the polymorphism Thr92Ala in Dio2 gene is associated with increased risk of mental retardation, insulin resistance in type 2 diabetic patients, reduced glucose availability in obese women, symptomatic osteoarthritis, Graves disease and arterial hypertension.

Implicated in

Entity name
Various cancers
Note
Although not completely understood, Dio2 gene expression and activity is altered in some tumors. It is under-expressed in papillary thyroid carcinomas (PTC). In follicular tumors, D2 activity is similar or elevated when compared to non tumoral tissues, and augmented in follicular adenomas. D2 is also highly expressed in medullar thyroid carcinoma. A higher expression of the Dio2 gene was also described in gliosarcoma, oligoastrocytoma, glioblastoma, oligodendroglioma and pituitary tumors. In contrast, meningioma does not express D2 activity. These differences might be related to the embrionary tumor origin. Mesothelioma expresses higher activity of D2, whereas osteosarcoma has diminished D2 activity.
Entity name
Insulin resistance
Note
Dio2 polymorphism Thr92Ala interacts with a polymorphism in PPAR gamma 2 gene and is associated with insulin resistance in diabetic patients. This Dio2 polymorphism is associated with a ~20% lower rate of glucose disposal in obese women than in non-obese women. Although the association between those two genes occurs in patients with insulin resistance, these results are contradictory in non diabetic population.
Entity name
Hypothyroidism
Note
Disruption in mouse Dio2 gene is associated with alterations in T4/T3 balance with elevated TSH levels, which demonstrates that the Dio2 gene is of critical importance in the feedback regulation of TSH secretion.
Entity name
Graves disease
Note
It is suggested that the Thr92Ala variant of the Dio2 gene is associated or might be in linkage disequilibrium with a functional DIO2 polymorphism which involves the development of Graves disease in a Russian population.
Entity name
Mental retardation
Note
A case control study in Chinese patients demonstrated that two allelic intronic SNPs (rs225010 (T/C) and rs225012 (A/G)) in the DIO2 gene could affect the amount of T3 available and in an iodine-deficient environment and partially determine on augmented risk of mental retardation. They found a positive association with mental retardation and the two intronic Dio2 polymorphisms but not with Dio2 Thr92Ala alone and concluded that the genetic variation in Dio2 determine the risk of development of mental retardation that could be due to alterations in the local amount of T3 available in the brain.
Entity name
Bone metabolism
Note
Dio2 is expressed in human and mouse osteoblast cells. In patients with differentiated thyroid carcinoma, the Dio2 Thr92Ala polymorphism is associated with a decreased femoral neck bone mineral density and higher bone turnover independent of serum thyroid hormone levels.
Entity name
Cardiomyopathy and arterial hypertension
Note
Dio2 gene expression is also markedly up-regulated in hearts of mice that develops hypothyroidism or eccentric hypertrophy after myocardial infarction. The Dio2 polymorphism Thr92Ala is also associated with increased risk for the development of hypertension.

Bibliography

Pubmed IDLast YearTitleAuthors

Other Information

Locus ID:

NCBI: 1734
MIM: 601413
HGNC: 2884
Ensembl: ENSG00000211448

Variants:

dbSNP: 1734
ClinVar: 1734
TCGA: ENSG00000211448
COSMIC: DIO2

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000211448ENST00000422005J3KQY5
ENSG00000211448ENST00000438257Q92813
ENSG00000211448ENST00000554188G3V3A8
ENSG00000211448ENST00000555750A0A024R6J8
ENSG00000211448ENST00000555844H0YJ42
ENSG00000211448ENST00000556811H0YJQ8
ENSG00000211448ENST00000557010Q92813
ENSG00000211448ENST00000557125G3V2A7

Expression (GTEx)

0
10
20
30
40
50
60
70
80
90

Pathways

PathwaySourceExternal ID
Thyroid hormone signaling pathwayKEGGhsa04919
MetabolismREACTOMER-HSA-1430728
Metabolism of amino acids and derivativesREACTOMER-HSA-71291
Amine-derived hormonesREACTOMER-HSA-209776
Thyroxine biosynthesisREACTOMER-HSA-209968
Regulation of thyroid hormone activityREACTOMER-HSA-350864

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA445857Thyroid NeoplasmsDiseaseVariantAnnotationnot associatedPD
PA450221levothyroxineChemicalVariantAnnotationnot associatedPD

References

Pubmed IDYearTitleCitations
191901132009Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients.75
191901132009Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients.75
161274642005Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans.72
183345782008Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis.63
183345782008Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis.63
203796142010Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.62
157979632005The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus.53
157979632005The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus.53
128470932003The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure.50
118726972002Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor.49

Citation

Ana Luiza Maia ; Simone Magagnin Wajner ; Leonardo B Leiria

DIO2 (deiodinase, iodothyronine, type II)

Atlas Genet Cytogenet Oncol Haematol. 2010-06-01

Online version: http://atlasgeneticsoncology.org/gene/44390/gene-fusions-explorer/